Long-term therapy for chronic hepatitis B: Hepatitis B virus DNA suppression leading to cirrhosis reversal

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 6, 2013, Pages 912-923

  Marcellin, Patrick ^a   Asselah, Tarik ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

Chronic hepatitis B; Cirrhosis; Fibrosis; Long term; Nucleotide nucleoside analogs

Indexed keywords

ADEFOVIR; DNA POLYMERASE; EMTRICITABINE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; PEGINTERFERON; RIBAVIRIN; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ANTIVIRAL THERAPY; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HISTOPATHOLOGY; HUMAN; KIDNEY TUBULE DISORDER; LACTIC ACIDOSIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER ENZYME BLOOD LEVEL; LIVER FAILURE; LIVER FIBROSIS; LONG TERM CARE; MONOTHERAPY; MORBIDITY; MORTALITY; MULTICENTER STUDY (TOPIC); MYALGIA; MYOPATHY; NEPHROTOXICITY; NEUROPATHY; OSTEOPENIA; PANCREAS ADENOCARCINOMA; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHYSICIAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SEROCONVERSION; SIDE EFFECT; STOMACH CANCER; TREATMENT DURATION; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN; COMPLICATION; DRUG EFFECTS; GENETICS; HEPATITIS B, CHRONIC; PATHOLOGY; REMISSION; TIME;

CLINICAL TRIALS AS TOPIC; DNA, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; REMISSION INDUCTION; TIME FACTORS;

EID: 84878204383     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12213     Document Type: Review

References (80)

1. World Health Organization. Hepatitis B Fact sheet No. 204, 2012. Cited 24 Oct 2012. Available from URL: http://www.who.int/mediacentre/factsheets/fs204/en/.
2. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J. Hepatol. 2012; 57: 167-185.
3. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ; Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-686.
4. Chen CJ, Yang HI, Su J etal. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
5. Liaw YF, Sung JJ, Chow WC etal. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 2004; 351: 1521-1531.
6. Lai CL, Chien RN, Leung NW etal. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med. 1998; 339: 61-68.
7. Dienstag JL, Schiff ER, Wright TL etal. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 1999; 341: 1256-1263.
8. Leung NW, Lai CL, Chang TT etal. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33: 1527-1532.
9. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32: 847-851.
10. Di Marco V, Marzano A, Lampertico P etal. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004; 40: 883-891.
11. Yuen MF, Seto WK, Chow DH etal. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir. Ther. 2007; 12: 1295-1303.
12. Lok AS, Lai CL, Leung N etal. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714-1722.
13. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30: 567-572.
14. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ etal. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-1751.
15. Marcellin P, Chang TT, Lim SG etal. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008; 48: 750-758.
16. Chang TT, Gish RG, de Man R etal. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2006; 354: 1001-1010.
17. Lai CL, Shouval D, Lok AS etal. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2006; 354: 1011-1020.
18. Gish RG, Lok AS, Chang TT etal. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133: 1437-1444.
19. Chang TT, Lai CL, Kew Yoon S etal. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 422-430.
20. Tenney DJ, Rose RE, Baldick CJ etal. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-1514.
21. Lai CL, Gane E, Liaw YF etal. Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med. 2007; 357: 2576-2588.
22. Liaw YF, Gane E, Leung N etal. Telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136: 486-495.
23. Marcellin P, Heathcote EJ, Buti M etal. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med. 2008; 359: 2442-2455.
24. van Bömmel F, de Man RA, Wedemeyer H etal. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010; 51: 73-80.
25. Heathcote EJ, Marcellin P, Buti M etal. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011; 140: 132-143.
26. Marcellin P, Gane E, Buti M etal. Regression of cirrhosis during tenofovir disoproxil fumarate treatment for chronic hepatitis B. Lancet 2013; 381: 468-475.
27. Buti M, Fung S, Gane E etal. Clinical, virological, serological and histological outcomes in cirrhotic patients with chronic hepatitis B (CHB) treated with tenofovir disoproxil fumarate (TDF) for up to 5 years. J. Hepatol. 2012; 56: S197.
28. Patterson SJ, George J, Strasser SI etal. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 2011; 60: 247-254.
29. Fung S, Kwan WCP, Fabri M etal. Efficacy and safety of tenofovir DF (TDF) in chronic hepatitis B virus infected patients with documented lamivudine-resistance (LAM-R). Hepatology 2012; 56: 200A.
30. Berg T, Marcellin P, Zoulim F etal. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology 2010; 139: 1207-1217.
31. Gane EJ, Wang Y, Liaw YF etal. Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. Liver Int. 2011; 31: 676-684.
32. Kim IH, Kwon DH, Kim SH, Kim SW, Lee SO, Lee ST. Long-term efficacy of continuous entecavir 0.5mg monotherapy in naïve chronic hepatitis b patients with partial virological response at week 48. Hepatology 2012; 56: 376A.
33. Kobashi H, Fujioka S, Kawaguchi M etal. Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B. Hepatol. Int. 2009; 3: 403-410.
34. Tenney DJ, Levine SM, Rose RE etal. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob. Agents Chemother. 2004; 48: 3498-3507.
35. Chen CH, Wang JH, Lu SN etal. Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants. Antivir. Ther. 2012; 17: 701-709.
36. Corsa AC, Liu Y, Mitchell BC, Flaherty BC, Miller MD, Kitrinos KM. No detectable resistance to tenofovir disoproxil fumarate (TDF) or TDF plus emtricitabine (FTC/TDF) combination therapy through 96 Weeks in chronic hepatitis B (CHB) patients with documented resistance to lamivudine (LAM). Hepatology 2012; 56: 382A.
37. Poynard T, McHutchison J, Manns M etal. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-1313.
38. George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 2009; 49: 729-738.
39. Veldt BJ, Heathcote EJ, Wedemeyer H etal. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann. Intern. Med. 2007; 147: 677-684.
40. Bruno S, Stroffolini T, Colombo M etal. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 579-587.
41. Maylin S, Martinot-Peignoux M, Moucari R etal. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008; 135: 821-829.
42. Dienstag JL, Goldin RD, Heathcote EJ etal. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124: 105-117.
43. Rizzetto M, Tassopoulos NC, Goldin RD etal. Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. J. Hepatol. 2005; 42: 173-179.
44. Chang TT, Liaw YF, Wu SS etal. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-893.
45. Hou J, Xu D, Shi G etal. Five year telbivudine treatment with effective viral suppression results in resolution of liver inflammation and fibrosis regression in patients with chronic hepatitis B. J. Hepatol. 2011; 54: S287.
46. Schiff ER, Lee SS, Chao Y-C etal. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin. Gastroenterol. Hepatol. 2011; 9: 274-276.
47. Yang LQ, Li XY, Wu Y, Chong Y. Risk factor analysis of HCC for chronic hepatitis B patients with nucleos(t)ide analogues therapy. Hepatology 2012; 56: 360A.
48. Chang TT, Lai CL, Chien RN etal. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J. Gastroenterol. Hepatol. 2004; 19: 1276-1282.
49. Marcellin P, Chang TT, Lim SG etal. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 2003; 348: 808-816.
50. Gilead Sciences International Limited. Summary of Product Characteristics: Adefovir. Cited 7 Nov 2012. Available from URL: http://www.medicines.org.uk/emc/document.aspx?documentid=12438&docType=SPC.
51. Zou XJ, Jiang XQ, Tian DY. Clinical features and risk factors of creatine kinase elevations and myopathy associated with telbivudine. J. Viral Hepat. 2011; 18: 892-896.
52. Marcellin P, Avila C, Wursthorn K etal. Telbivudine (LdT) plus peg-interferon in HBeAg-positive chronic hepatitis B-very potent antiviral efficacy but risk of peripheral neuropathy. J. Hepatol. 2010; 52: S6.
53. Manns MP, Akarca US, Chang TT etal. Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901. Expert Opin. Drug Saf. 2012; 11: 361-368.
54. Lange CM, Bojunga J, Hofmann WP etal. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009; 50: 2001-2006.
55. Liaw YF, Raptopoulou-Gigi M, Cheinquer H etal. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology 2011; 54: 91-100.
56. Gara N, Zhao X, Collins MT etal. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Aliment. Pharmacol. Ther. 2012; 35: 1317-1325.
57. Manolakopoulos S, Striki A, Papatheodoridis GV. Letter: renal tubular dysfunction during nucleotide analogue therapy in chronic hepatitis B. Aliment. Pharmacol. Ther. 2012;36: 992-993.
58. Lok AS, Trinh H, Carosi G etal. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. Gastroenterology 2012; 143: 619-628.
59. Calmy A, Fux CA, Norris R etal. Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J. Infect. Dis. 2009; 200: 1746-1754.
60. McComsey GA, Kitch D, Daar ES etal. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J. Infect. Dis. 2011; 203: 1791-1801.
61. Cassetti I, Madruga JV, Suleiman JM etal.; Study 903E Team. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1-infected patients. HIV Clin. Trials 2007; 8: 164-172.
62. Marcellin P, Buti M, Gane EJ etal. Six years of treatment with tenofovir DF for chronic hepatitis B virus infection is safe and well tolerated and associated with sustained virological, biochemical and serological responses with no detectable resistance. Hepatology 2012; 56: 374A.
63. Novartis Europharm Limited. Summary of Product Characteristics: Telbivudine. Cited 7 Nov 2012. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000713/WC500049337.pdf.
64. BRISTOL-MYERS SQUIBB PHARMA EEIG. Summary of Product Characteristics: Entecavir. Cited 7 Nov 2012. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000623/WC500051984.pdf.
65. Glaxo Group Ltd. Summary of Product Characteristics: Lamivudine. Cited 7 Nov 2012. Available from URL: http://www.medicines.org.uk/emc/medicine/3273/SPC.
66. Gilead Sciences International Limited. Summary of Product Characteristics: Tenofovir. Cited 7 Nov 2012. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000419/WC500051737.pdf.
67. Brown RS Jr, Verna EC, Pereira MR etal. Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: findings from the Antiretroviral Pregnancy Registry. J. Hepatol. 2012; 57: 953-959.
68. Buti M, Morillas RM, Prieto M etal. A viral load reduction >3 log at 12 week of entecavir treatment correlated with HBe seroconversion in HBeag positive patients. Results from a real-life setting study (the ORIENTE study). Hepatology 2010;52: 523A-524.
69. Zoutendijk R, Reijnders JG, Brown A etal. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response. Hepatology 2011; 54: 443-451.
70. Lampertico P, Soffredini R, Vigano M etal. Entecavir treatment for NUC naïve, field practice patients with chronic hepatitis B: excellent viral suppression and safety profile over 5 years of treatment. Hepatology 2012; 56: 370A.
71. Liu Y, Yuan Z, Tang H etal. Entecavir monotherapy in NA naive chronic hepatitis B and cirrhosis patients: a retrospective and prospective cohort study over 4 years of treatment. Hepatology 2012; 56: 363A.
72. Lampertico P, Soffrendi R, Vigano M etal. Tenofovir monotherapy suppressed viral suppression in most field practice, treatment-naïve patients with chronic hepatitis B followed for 3 years in a multicenter European study. Hepatology 2012; 56: 389A.
73. Marcellin P, Zoulim F, Causse X etal. High efficacy and safety of tenofovir DF in 441 naïve and NUC-experienced chronic hepatitis B patients: a real life multicentre prospective cohort study. J. Hepatol. 2012; 56: S210.
74. Petersen J, Heyne R, Mauss S etal. Tenofovir DF for chronic hepatitis B patients in field practice-results from the GEMINIS German multicentre observational study. J. Hepatol. 2012; 56: S212.
75. van Bommel F, Zoutendijk R, de Man R etal. A European field study of the efficacy and safety of tenefovir disoproxil fumerate (TDF) monotherapy in patients with prior failure to other nucleoside/nucleotide analogues. J. Hepatol. 2012; 56: S216.
76. Marcellin P, Zoulim F, Causse X etal. Tenofovir DF treatment is safe and well tolerated in chronic hepatitis B (CHB) patients with decreased glomerular filtration rate. J. Hepatol. 2012; 56: S210.
77. Gish RG, Clark MD, Kane SD, Shaw RE, Mangahas MF, Baqai S. Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B. Clin. Gastroenterol. Hepatol. 2012; 10: 941-946.
78. Roberts S, Gordon A, McLean C etal. Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis. Clin. Gastroenterol. Hepatol. 2007;5: 932-937.
79. Poynard T, Ngo Y, Munteanu M, Thabut D, Ratziu V. Noninvasive markers of hepatic fibrosis in chronic hepatitis B. Curr. Hepat. Rep. 2011; 10: 87-97.
80. Estrabaud E, Vidaud M, Marcellin P, Asselah T. Genomics and HCV infection: progression of fibrosis and treatment response. J. Hepatol. 2012; 57: 1110-1125.